Efficacy and safety of long-term evolocumab use among Asian subjects - A subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (fourier) trial -
Version 2 2024-06-13, 14:52Version 2 2024-06-13, 14:52
Version 1 2021-11-18, 08:50Version 1 2021-11-18, 08:50
journal contribution
posted on 2024-06-13, 14:52authored byAC Keech, K Oyama, PS Sever, M Tang, SA Murphy, A Hirayama, C Lu, L Tay, PC Deedwania, CW Siu, AL Pineda, D Choi, MJ Charng, J Amerena, WAW Ahmad, VK Chopra, TR Pedersen, RP Giugliano, MS Sabatine
Efficacy and safety of long-term evolocumab use among Asian subjects - A subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (fourier) trial -